Contrasting PolyPid (NASDAQ:PYPD) and BeOne Medicines (NASDAQ:ONC)

PolyPid (NASDAQ:PYPD) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Profitability

This table compares PolyPid and BeOne Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-291.42%	-131.82%
BeOne Medicines	5.37%	10.70%	6.03%

Volatility & Risk

PolyPid has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for PolyPid and BeOne Medicines, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1	0	5	0	2.67
BeOne Medicines	1	2	11	0	2.71

PolyPid currently has a consensus price target of $12.25, suggesting a potential upside of 161.19%. BeOne Medicines has a consensus price target of $385.08, suggesting a potential upside of 21.07%. Given PolyPid’s higher probable upside, equities analysts plainly believe PolyPid is more favorable than BeOne Medicines.

Institutional and Insider Ownership

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 6.6% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares PolyPid and BeOne Medicines”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17 million	($2.26)	-2.08
BeOne Medicines	$5.34 billion	6.53	$286.93 million	$2.52	126.22

BeOne Medicines has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Summary

BeOne Medicines beats PolyPid on 10 of the 13 factors compared between the two stocks.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.